AEMD
Aethlon Medical, Inc.
There isn't enough reported data to score AEMD yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
AEMD Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
AEMD's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AEMD PE Valuation
AEMD has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AEMD Forward outlook
There aren't enough analyst estimates for AEMD to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
AEMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | -$91.30 | +$337.70 |
| Q4 2025 | -$234.45 | +$381.55 |
| Q3 2025 | -$274.20 | +$837.80 |
| Q2 2025 | -$335.50 | +$1,184.50 |
| Q1 2025 | -$429.00 | +$1,515.00 |
| Q4 2024 | -$616.00 | +$1,380.00 |
| Q3 2024 | -$1,112.00 | +$816.00 |
| Q2 2024 | -$1,520.00 | +$640.00 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 121% for AEMD versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
AEMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2023 | $574.2K | +4278% |
| Q1 2022 | $13.1K | -62% |
| Q4 2021 | $17.1K | -97% |
| Q1 2021 | $34.2K | -83% |
| Q4 2020 | $624.9K | +51% |
AEMD has the stronger quarterly revenue trend. Revenue is up 4,278% for AEMD versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2023 | -432% | +28432 points |
| Q1 2022 | -28863% | -22248 points |
| Q4 2021 | -14769% | -14378 points |
| Q3 2021 | -1522% | N/A |
| Q2 2021 | -1590% | N/A |
| Q1 2021 | -6615% | -5752 points |
| Q4 2020 | -391% | -179 points |
| Q1 2020 | -864% | N/A |
AEMD's operating margin was −432% last quarter, up 1159 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
AEMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.7M | -$79.9K |
| Q2 2026 | -$1.9M | -$190.8K |
| Q1 2026 | -$1.8M | -$82K |
| Q3 2025 | -$1.7M | +$555.8K |
| Q2 2025 | -$1.7M | +$32.6K |
| Q1 2025 | -$1.7M | +$899.9K |
| Q4 2024 | -$2M | +$373.7K |
| Q3 2024 | -$2.2M | +$496.4K |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with AEMD at up 21%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
AEMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +648% | +873K shares |
| 1 year | +2326% | +966K shares |
| 3 years | +19525% | +1M shares |
| 5 years | +33230% | +1M shares |
| Available history | +139451% | +1M shares |
AEMD has 1M diluted shares, up 2326% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AEMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AEMD Net Leverage
AEMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AEMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.9 | Neutral |
| Stochastic | 50.5 | Neutral |
AEMD's weekly RSI is 43 (neutral) and its Stochastic is 51 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AEMD PE vs Healthcare Sector
AEMD has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AEMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.68 | 1.8% below |
| 20 week MA | $4.14 | 35% above |
| 50 week MA | $8.58 | 35% below |
| 100 week MA | $66.1 | 92% below |
| 200 week MA | $452.7 | 99% below |
AEMD's trend is mixed: it's above one of its five weekly moving averages, and 99% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AEMD on trend strength, trading above more of its moving averages.
AEMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3,680.0 | $8,640.0 | +135% |
| 2021 | $8,640.0 | $8,560.0 | -0.9% |
| 2022 | $8,560.0 | $1,004.0 | -88% |
| 2023 | $1,004.0 | $876.0 | -13% |
| 2024 | $876.0 | $242.3 | -72% |
| 2025 | $242.3 | $12.8 | -95% |
| 2026 YTD | $12.8 | $5.58 | -56% |
AEMD has finished five years in a row lower, and it's down 56% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AEMD on returns for 2026, with the stronger performance.